Evicenter
MarkdownMedical informationP&T meetings
Ifezuntirgene inilparvovec (AMT-130)

Huntington's disease

Manufacturer
uniQure
Launch
Not announced
Last updated
291 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
AADCAromatic L-amino acid decarboxylase
AADCDAromatic L-amino acid decarboxylase deficiency
AANAmerican Academy of Neurology
AAVAdeno-associated virus
AAV1Adeno-associated virus serotype 1
AAV2Adeno-associated virus serotype 2
AAV5Adeno-associated virus serotype 5
AAV9Adeno-associated virus serotype 9
ACPAdvance care planning
adj-R2Adjusted R-squared
ADMAntidopaminergic medication
AEAdverse event
AHFSAmerican Hospital Formulary Service
ALTAlanine aminotransferase
ANOVAAnalysis of variance
anti-HBcHepatitis B core antibody
anti-HCVHepatitis C virus antibody
AOHD, AoHDAdult-onset Huntington's disease
APDAntipsychotic drug
ASAdvanced stage
ASNSD1Asparagine synthetase domain containing 1
ASOAntisense oligonucleotide
ATIMPAdvanced therapy investigational medicinal product
BLABiologics License Application
C-SSRSColumbia-Suicide Severity Rating Scale
CAGCytosine-adenine-guanine trinucleotide repeat
CAPCAG-age product
CAP100CAG-age product scaled to 100 at the expected age of onset
CATCommittee for Advanced Therapies (European Medicines Agency)
CBERCenter for Biologics Evaluation and Research (US Food and Drug Administration)
CEDConvection-enhanced delivery
CEPACComparative Effectiveness Public Advisory Council
CGI-SClinical Global Impression of Severity
CHDICure Huntington's Disease Initiative
CIConfidence interval
cis-eQTLCis-acting expression quantitative trait locus
CMCChemistry, manufacturing, and controls
CMSCenters for Medicare & Medicaid Services
CNCaudate nucleus
CNSCentral nervous system
COECenter of Excellence
COHORTCooperative Huntington's Observational Research Trial
COVID-19Coronavirus disease 2019
CRDCentre for Rare Disorders (Oslo University Hospital)
CSFCerebrospinal fluid
CSHLCold Spring Harbor Laboratory
CSICaregiver Strain Index
CTISClinical Trials Information System (European Union)
cUDHRSComposite Unified Huntington's Disease Rating Scale (spelling in a quoted source)
cUHDRSComposite Unified Huntington's Disease Rating Scale
CYP2D6Cytochrome P450 2D6
DARPP-32Dopamine- and cAMP-regulated phosphoprotein of 32 kDa
DCLDiagnostic confidence level
DMDDuchenne muscular dystrophy
dMRIDiffusion magnetic resonance imaging
DMTDisease-modifying treatment
DNADeoxyribonucleic acid
DSMBData Safety Monitoring Board
ECGElectrocardiogram
eCRFElectronic case record form
EHDNEuropean Huntington's Disease Network
EMExtensive metabolizer
EMAEuropean Medicines Agency
EQ-5DEuroQol 5-dimension questionnaire
EQ-5D-3LEuroQol 5-dimension questionnaire, 3-level version
EQ-5D-5LEuroQol 5-dimension questionnaire, 5-level version
ESEarly stage
EUEuropean Union
EVExtracellular vesicle
evLYEqual value of life year
FAN1FANCD2 and FANCI associated nuclease 1
FDAUS Food and Drug Administration
FHDFirst human dose
FIHFirst-in-human
First-HDFirst Time Use of SD-809 in Huntington Disease trial
FLFull-length
FOCPFemale of childbearing potential
GC, gcGenetic counseling (GC); genome copies (gc)
GCITGene-based, Cellular and other Innovative Therapies (Aetna network)
GENEROUSGenerating Cost Reductions for U.S. Medicaid (Model)
GFAPGlial fibrillary acidic protein
GFPGreen fluorescent protein
GINAGenetic Information Nondiscrimination Act
GMPGood manufacturing practice
GPGeneral population
GP-CPGeneral population care partners
GRADEGrading of Recommendations Assessment, Development and Evaluation
GTxGene therapy
GWAGenome-wide association
GWASGenome-wide association study
H-QoL-IHuntington Quality of Life Instrument
HADSHospital Anxiety and Depression Scale
HBPBHealth Benefit Price Benchmark
HBsAgHepatitis B surface antigen
HCVHepatitis C virus
HDHuntington's disease
HD-CABHuntington's Disease Cognitive Assessment Battery
HD-CPHuntington's disease care partners
HD-CSFHuntington's Disease Cerebrospinal Fluid study
HD-ISSHuntington's Disease Integrated Staging System
HDBOIHuntington's Disease Burden of Illness study
HDGECHuntington's disease gene-expansion carrier
HDQLIFEHuntington Disease Health-related Quality of Life measurement system
HDSAHuntington's Disease Society of America
HEHighly expanded (CAG repeat subgroup)
HIVHuman immunodeficiency virus
HRHazard ratio
HRQoLHealth-related quality of life
HRUHealthcare resource utilization
HSGHuntington Study Group
HSUVHealth state utility value
HTTHuntingtin gene or protein
HTT1aTruncated huntingtin transcript containing exon 1 and part of intron 1
HTTexon1Huntingtin exon 1 protein
Iba1Ionized calcium-binding adapter molecule 1
ICInformal caregiver
ICC2,1Intraclass correlation coefficient, two-way random-effects model, single measure
ICERInstitute for Clinical and Economic Review; incremental cost-effectiveness ratio
iDMCIndependent Data Monitoring Committee
IHDIndividuals with Huntington's disease
IMPInvestigational medicinal product
INDInvestigational New Drug application
IPDIndividuals with Parkinson's disease
IPiNInstitute of Psychiatry and Neurology, Warsaw (Instytut Psychiatrii i Neurologii)
IQRInterquartile range
ISIndependence Scale
ISS-2, ISS-3Huntington's Disease Integrated Staging System stage 2, stage 3
IVFIn vitro fertilization
JHDJuvenile Huntington's disease
JoHDJuvenile-onset Huntington's disease
KIKnock-in
KMKaplan-Meier
LDLLow-density lipoprotein
LELow expansion (CAG repeat subgroup)
LIG1DNA ligase 1
LoHDLate-onset Huntington's disease
LSLeast squares
LSMLeast squares mean
LTCLong-term care
LTFULong-term follow-up
MAMarketing authorisation
MAAMarketing Authorisation Application
MBPMedicaid Best Price
MCSIModified Caregiver Strain Index
MDSInternational Parkinson and Movement Disorder Society; movement disorders specialist
MDTMultidisciplinary team
mgMilligram
MHRAMedicines and Healthcare products Regulatory Agency (United Kingdom)
mHTTMutant huntingtin protein
miHTTEngineered microRNA targeting the huntingtin exon 1 sequence
miRNAMicroRNA
mLMilliliter
MLH1MutL homolog 1
MMRDNA mismatch repair
MMRMMixed-effects model for repeated measures
MoCAMontreal Cognitive Assessment
MRIMagnetic resonance imaging
mRNAMessenger RNA
MRSMagnetic resonance spectroscopy
MSMid stage
MS-DRGMedicare Severity Diagnosis Related Group
MSH3MutS homolog 3
mtHTTMutant huntingtin
NAbNeutralizing antibody
NCDRNorwegian Cause of Death Registry
NeuNNeuronal nuclei (neuron-specific nuclear protein)
Neuro-QoL, NeuroQoLQuality of Life in Neurological Disorders measurement system
NfLNeurofilament light chain
NHPNonhuman primate
NHSNational Health Service
OBAOutcomes-based agreement
PBAProblem Behaviors Assessment
PCPalliative care
PCAPrincipal component analysis
PCPPrimary care physician
PD-CPParkinson's disease care partners
PDSPeriodic dataset (Enroll-HD)
PDUFAPrescription Drug User Fee Act
PEGPercutaneous endoscopic gastrostomy
PFDPrefunctional decline
PGICPatient Global Impression of Change
PHQ-9Patient Health Questionnaire-9
PIPrincipal investigator
PINPrognostic Index Normed
PMPoor metabolizer
PMPMPer member per month
PMS1PMS1 homolog 1, mismatch repair system component (postmeiotic segregation increased 1)
PMS2PMS1 homolog 2, mismatch repair system component (postmeiotic segregation increased 2)
PoCProof of concept
PPIE-CPatient Public Involvement Engagement-Caregiver questionnaire
PPIE-PPatient Public Involvement Engagement-Patient questionnaire
PPPMPer patient per month
PPQProcess Performance Qualification
PREDICT-HDNeurobiological Predictors of Huntington's Disease study
preHDPremanifest Huntington's disease
preHD-APremanifest Huntington's disease group A (further from predicted onset)
preHD-BPremanifest Huntington's disease group B (closer to predicted onset)
pri-miRNAPrimary microRNA transcript
PRIMEPriority Medicines (European Medicines Agency scheme)
PROMISPatient-Reported Outcomes Measurement Information System
PROOF-HDPridopidine Outcome on Function in Huntington Disease trial
PSPropensity score
PSAProbabilistic sensitivity analysis
PSMPropensity score-matched
PTProthrombin time
PTTPartial thromboplastin time
PwHBPeople with hemophilia B
PwHDPeople with Huntington's disease
PYPerson-years
Q-MotorQuantitative Motor testing
Q1, Q3First quarter, third quarter
QALYQuality-adjusted life year
QoLQuality of life
qPCRQuantitative polymerase chain reaction
rAAV5Recombinant adeno-associated virus serotype 5
RCTRandomized controlled trial
RMATRegenerative Medicine Advanced Therapy
RNARibonucleic acid
RNAiRNA interference
S/NSignal-to-noise
S1RSigma-1 receptor
SAESerious adverse event
SAPStatistical analysis plan
SCA1Spinocerebellar ataxia type 1
SCA3Spinocerebellar ataxia type 3
SDStandard deviation
SDMTSymbol Digit Modalities Test
SEStandard error
SECUS Securities and Exchange Commission
SFShoulson and Fahn (staging system)
SF-36v136-Item Short Form Health Survey, version 1
SF-6DShort-Form 6-Dimension
SF1, SF2Shoulson and Fahn stage 1, stage 2
SMASpinal muscular atrophy
SMDTSymbol Digit Modalities Test (spelling in a quoted source)
SNFSkilled nursing facility
SNPSingle nucleotide polymorphism
SNRISerotonin-norepinephrine reuptake inhibitor
SoCStandard of care
SPNStriatal projection neuron
SSRISelective serotonin reuptake inhibitor
SSTSingle or short-term therapy
STBSuicidal thoughts and behavior
SUSARSuspected unexpected serious adverse reaction
SWRStroop Word Reading
SWRTStroop Word Reading Test
TBZTetrabenazine
TEAETreatment-emergent adverse event
TFCTotal Functional Capacity
tgHDTransgenic Huntington's disease (minipig model)
TMSTotal Motor Score
tNAATotal N-acetylaspartate
TTOTime trade-off
UHDRSUnified Huntington's Disease Rating Scale
UKUnited Kingdom
ULNUpper limit of normal
US, USAUnited States
USDUS dollars
VCUVirginia Commonwealth University
vg, VGVector genomes
VMAT, VMAT2Vesicular monoamine transporter 2
WACWholesale acquisition cost
WHOWorld Health Organization
WMWhite matter
wtHTTWild-type huntingtin
WTPWillingness to pay
XRExtended-release
Y1 to Y4Year 1 to year 4
YKL-40Chitinase-3-like protein 1